NephroPlus Q3 FY26 results post-IPO: consol revenue up 32%, PAT rises 60% YoY

Revenue Growth 20pctPat Growth 25pctPat NegativeExceptional ItemResults View source PDF Explain this filing

NEPHROPLUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+7.8%Reaction day

₹538.00

prior close

₹557.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.5%+8.3% vs market

Healthcare Service Provider peers, median of 24sector-0.3%+8.1% vs sector

On the reaction day the stock moved 8.3 pts more than Nifty Microcap 250 and 8.1 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.1

10m

+1.4

15m

+2.0

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+7.8-0.5+8.3-0.3+8.1

Next day

+7.2-1.0+8.3-0.6+7.9

+6.9-2.5+9.4-1.4+8.3

+3.8-3.2+7.0-1.5+5.3

+8.8-2.2+11.0-2.0+10.7

+8.3-1.9+10.3-2.6+11.0

+3.3-3.5+6.8-2.7+6.0

15d

+3.1-8.8+11.9-7.6+10.8

+7.2-9.3+16.5-8.6+15.8

+6.4-4.5+10.9-7.0+13.4

+6.4+5.4+1.0-0.3+6.7

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 24Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

First quarterly filing since Dec 17, 2025 IPO listing. Q3 FY26 consolidated revenue grew 31.7% YoY to Rs 2,597.29M; PAT rose 60.3% to Rs 322.40M. Nine-month consol revenue up 36.6% to Rs 7,332.30M, PAT up 10% to Rs 464.70M. Standalone 9M shows Rs 189.48M loss, mostly due to Rs 371.89M non-cash, one-time FVTPL interest on pre-IPO instruments. Unmodified auditor review by B S R and Co.

Likely market impact

Strong operating momentum post-listing. Standalone loss reflects one-time IPO accounting, not business health.